Article info
PDFLetter
Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone
- Correspondence to Kevin Chevalier, Rheumatology, Hospital Bicetre, 94270 Le Kremlin-Bicêtre, France; kevinchevalier05{at}gmail.com
Citation
Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone
Publication history
- Received April 3, 2020
- Revised April 14, 2020
- Accepted April 18, 2020
- First published May 12, 2020.
Online issue publication
May 12, 2021
Article Versions
- Previous version (14 August 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.